- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic plaque psoriasis (CPP)
- Meeting Date: November 2023
- Public Summary Document (PSD) November 2023 PBAC Meeting - (PDF 841KB)
- Public Summary Document (PSD) November 2023 PBAC Meeting - (Word 259KB)
Risankizumab – November 2023
Risankizumab: Injection 150 mg in 1 mL pre-filled syringe, Injection 150 mg in 1 mL pre-filled pen; Skyrizi®
Last updated
1 March 2024